FindTrial
Sign In

[177Lu]Lu-PSMAI&T radioligand therapy (PSMA-RLT) for patients with prostate cancer and biochemical but not radio-morphological local recurrence after primary therapy with curative intent: A Prospective Phase II Pilot Study

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-519348-34-00
Enrollment
26
Registered
2024-12-09
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate carcinoma

Brief summary

PSA response in term of PSA decline of ≥ 50% from baseline value. • Emerge therapy toxicity in terms of pathological reduction of values of blood count, kidney and liver functions from baseline levels assessed by CTCAE (v5.0).

Interventions

DRUGLocametz 25 micrograms kit for radiopharmaceutical preparation
DRUGTECEOS Trockenstechampullen

Sponsors

Medical University Of Vienna
Lead SponsorOTHER

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
PSA response in term of PSA decline of ≥ 50% from baseline value. • Emerge therapy toxicity in terms of pathological reduction of values of blood count, kidney and liver functions from baseline levels assessed by CTCAE (v5.0).—

Countries

Austria

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026